6. Prostate Cancer Blood Test, APIFINY, Being Promoted in US by Aeterna Zentaris
Aeterna Zentaris Inc. announced it has begun promoting APIFINY, the only non-PSA blood test for the evaluation of prostate cancer risk, in the U.S. under a co-marketing agreement with Armune BioScience, Inc. Under the agreement, Zentaris will promote APIFINY to designated medical professionals in 20 American territories, and receive a commission for each test that results from its promotion, the company says in its press release.